Abstract |
Beta-blocking drugs that prevent cranial vasodilatation are potentially valuable in the prophylaxis of migraine. Forty-nine patients with either classic or common migraine were treated with propranolol 160 mg/day for an average of six months. The first 30 of the patients to respond well to this treatment then participated in a double-blind cross-over trial with a placebo and propranolol. The mean frequency of headache attacks was significantly reduced by propranolol. None of the patients expressed a preference for placebo. Propranolol seems to be an effective prophylactic for common and classic migraine but the antimigraine properties of the various beta-blocking agents probably differ.
|
Authors | T E Wideroe, T Vigander |
Journal | British medical journal
(Br Med J)
Vol. 2
Issue 5921
Pg. 699-701
(Jun 29 1974)
ISSN: 0007-1447 [Print] England |
PMID | 4604977
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
|
Chemical References |
|
Topics |
- Clinical Trials as Topic
- Female
- Humans
- Male
- Migraine Disorders
(drug therapy, prevention & control)
- Placebos
- Propranolol
(adverse effects, pharmacology, therapeutic use)
- Respiration
(drug effects)
- Respiratory Tract Diseases
(chemically induced)
|